Bristol-Myers Squibb will acquire Celgene in blockbuster $74B deal
In a blockbuster deal between two of biopharma’s largest players, Bristol-Myers Squibb said Thursday it plans to buy Celgene for $74 billion.
The transaction — the fourth-largest ever in pharma — joins two of the largest companies in oncology, both of which have been facing setbacks. Bristol-Myers pioneered the use of cancer medicines that work by priming
